Anti-Canine IL-31 Reference Antibody (Tirnovetmab, RUO) (CV678016)

Name: Anti-Canine IL-31 Reference Antibody (Tirnovetmab, RUO)
Brand: abinScience
SKU: CV678016
Price: 176 USD
Availability: InStock

Datasheet Compartir producto Copiar información

Precio(USD):

Especificación:

100ug
1mg
5mg
10mg
25mg
50mg
100mg

Número:

Contáctenos

Vista general
Imágenes
Referencias
Datasheet
SDS

Vista general

Número de catálogo

CV678016

Descripción

Tirnovetmab (CV678016) is a research-grade recombinant antibody targeting IL-31. Produced in mammalian cells with native-like glycosylation.

Highlights

●Research Grade — For PK/PD studies, assay development, and ADA research.
●Native Glycosylation — Mammalian expression ensures native-like patterns.

Reactividad de especies

Canine

Aplicaciones

ELISA, Bioactivity: FACS, Functional assay, Research in vivo

Especie huésped

Canine

Clonalidad

Monoclonal

Isotipo

IgG2-Kappa

Sistema de expresión

Mammalian cells

Objetivo

IL-31, Interleukin-31, IL31

Nivel de endotoxinas

< 10 EU/mg

Pureza

>95% purity as determined by SDS-PAGE.

Purificación

Protein A/G purified from cell culture supernatant.

Número de acceso

C7G0W1

Forma

Liquid

Buffer de almacenamiento

0.01M PBS pH 7.4

Consulte la información específica del buffer en la copia impresa del datasheet o en el COA específico del lote.

Información de uso del producto

Aplicación	Dilución
ELISA	1:2000-1:20000

Estabilidad y almacenamiento

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.

Nombres alternativos

KIND-016, 2364504-80-1

Fondo

Tirnovetmab (KIND-016) is an antibody. Tirnovetmab can be used for experiment research.
• The IL-4, IL-13 and IL-31 pathways in atopic dermatitis., PMID:34106037
• IL-31-dependent neurogenic inflammation restrains cutaneous type 2 immune response in allergic dermatitis., PMID:37831760
• Interleukin-31: The "itchy" cytokine in inflammation and therapy., PMID:33629401
• A sensory neuron-expressed IL-31 receptor mediates T helper cell-dependent itch: Involvement of TRPV1 and TRPA1., PMID:24373353
• Seladelpar treatment reduces IL-31 and pruritus in patients with primary biliary cholangitis., PMID:38117036
• Nemolizumab: First Approval., PMID:35834124
• Nemolizumab: An Innovative Biologic Treatment to Control Interleukin 31, a Key Mediator in Atopic Dermatitis and Prurigo Nodularis., PMID:35842249
• The Cytokine TGF-β Induces Interleukin-31 Expression from Dermal Dendritic Cells to Activate Sensory Neurons and Stimulate Wound Itching., PMID:32673566
• Pruritus as a Distinctive Feature of Type 2 Inflammation., PMID:33807098
• Targeting Interleukin-31 in Prurigo., PMID:37888922

Nota

For research use only. Not suitable for clinical or therapeutic use.

Imágenes